Dossier assessment
Pembrolizumab (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Pembrolizumab (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Pembrolizumab (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with advanced or recurrent endometrial cancer whose disease has progressed during or after prior platinum-based therapy at any stage of the disease when surgery or radiation to cure the cancer is not an option for them
- Patients for whom doxorubicin or paclitaxel is the suitable therapy according to physician’s choice: indication of a considerable added benefit
- Patients for whom a therapy option other than doxorubicin or paclitaxel is the suitable therapy according to physician’s choice: added benefit not proven
Press releases
Lenvatinib and pembrolizumab in endometrial cancer: patients live clearly longer
Additional information
Federal Joint Committee (G-BA)
2022-07-07 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A21-164
- Commission
- Commission awarded on 14.12.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2022-04-19.
Connected Projects
-
Dossier assessment
Pembrolizumab (breast cancer, triple-negative, locally recurrent/metastatic, in combination with chemotherapy) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (oesophageal cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (colorectal cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (urothelial carcinoma first line treatment) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed
-
Dossier assessment
Pembrolizumab (Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (head and neck squamous cell carcinoma, combination therapy) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (head and neck squamous cell carcinoma, monotherapy) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (combination with axitinib, renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (squamous non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (non-squamous non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (melanoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (urothelial carcinoma, first line) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Status: Commission completed
-
Dossier assessment
Pembrolizumab (head and neck squamous cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (classical Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Pembrolizumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Pembrolizumab (endometrial carcinoma) - Addendum to Commission A21-164
Status: Commission completed
-
Dossier assessment
Pembrolizumab (head and neck squamous cell carcinoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (endometrial carcinoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (cervical cancer, combination with chemoradiotherapy) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (TNBC, neoadjuvant and adjuvant) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed
-
Dossier assessment
Pembrolizumab (urothelial cancer, first line) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to § 35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (biliary cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (NSCLC, adjuvant) – Benefit assessment according to § 35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (gastric cancer, HER2-negative) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (gastric or gastro-oesophageal junction adenocarcinoma, HER2-positive) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (pleural mesothelioma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (breast cancer) - Benefit assessment according to § 35a Social Code Book V
Status: Commission completed